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 Thyroid hormone plays a vital role in growth and metabolism.  Its action is 
mediated by multiple receptors including thyroid hormone receptor α 1 (TRα1).  TRα1 is 
primarily a nuclear protein, but it has been found to shuttle rapidly between the nucleus 
and cytoplasm.  Recently, mutated variants of TRα1 have been found to cause Resistance 
to Thyroid Hormone α syndrome (RTHα).  Over 20 different mutations in patients have 
been described including amino acid substitutions at position 384 in human (h) TRα1 
from arginine (R) to either cysteine (C) or histidine (H). One of the potential mechanisms 
of the disorder is mislocalization of the receptor within the cell.  To test this hypothesis, 
the distribution of these two TRα1 mutations associated with RTHα was assessed by 
fluorescence microscopy after transfection of HeLa (human) cells with expression 
plasmids for GFP-tagged hTRα1_R384C and hTRα1_R384H.  Both RTHα mutants were 
found to have a significantly larger cytoplasmic population than wild type TRα1.  This 
suggests that the mislocalization of the receptor within the cell could contribute to the 





I. General Introduction 
The endocrine system is the body’s way to maintain homeostasis while in an ever-
changing environment.  Hormones are released into the bloodstream and delivered to 
their target tissues, where they enact a wide variety of responses, including changing 
gene transcription.  One of the most important hormone pathways is thyroid hormone and 
its receptors.  When the thyroid hormone pathway is not functioning properly, it can lead 
to issues with metabolism and growth and development.  In this thesis two mutations in 
thyroid hormone receptor α1 that are known to cause Resistance to Thyroid Hormone 
syndrome were investigated for their impact on receptor intracellular localization. 
II. Hypothalamic-Pituitary-Thyroid (HPT) Axis 
The hypothalamic-pituitary-thyroid (HPT) axis controls the production and 
release of one of the largest hormone signaling pathways in the human body.  The HPT 
axis is a feedback loop, in which the final product, thyroid hormone, goes back and 
inhibits the pathway (Anyetei-Anum et al. 2018) (Fig. 1).  The hypothalamus releases 
thyrotropin-releasing hormone (TRH) into hypothalamic-pituitary circulation.  TRH acts 
on the anterior pituitary gland to stimulate the production and release of thyrotropin 
(TSH), a glycoprotein.  TSH then acts on thyroid follicular cells to start a cAMP 
regulated signaling cascade, which results in the synthesis and release of thyroid hormone 
into the circulatory system (Sidhaye & Wondisford 2012).   





Figure 1: An overview of the HPT axis. 
 
III. Thyroid Hormone 
Thyroid hormone is usually found in one of two forms in circulation, thyroxine 
(T4) or triiodothyronine (T3) (Fig. 2).  Circulating levels of T4 are generally much higher 
than those of T3, and most circulating thyroid hormones are bound to serum carrying 
proteins, such as albumin, in a reversible manner, as both forms are non-soluble due to 
their hydrophobicity (Norris 2006).  The hormones eventually reach their target tissue 
and are transported into the cell through monocarboxylate transporters (MCTs), 
specifically MCT8 and MCT10.  Hydrophobic hormones are usually able to diffuse 
through the plasma membrane unaided, but thyroid hormones use transporters to further 
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increase the regulation of the system.  MCT8 has been studied the most thoroughly and 
appears to only transport thyroid hormone, with a higher affinity for T3 (Anyetei-Anum et 
al. 2018). 
 
Figure 2: Structure of thyroid hormones, T3 and T4. (modified from Lin et al. 2011) 
Once the hormones have been taken up into the cells of their target tissue, T3, the 
biologically active form, diffuses through the cytosol and into the nucleus, where it can 
bind to thyroid hormone receptors (TRs) and affect transcription and gene expression.  T4 
has little biological activity and must be converted to T3 once in the cell.  This conversion 
is done through the action of cytoplasmic type III deiodinase, which removes the iodine 
on the 5-carbon of T4 (Norris 2006).  However, thyroid hormone action can be changed 
by other deiodinases.  T4 can also be inactivated by being cleaved into to reverse T3 (rT3), 
where the iodine on the 5-carbon is removed instead.  Both T3 and rT3 can be further 
modified into the active hormone T2 or the inactive version 3,3-T2, respectively.  Both 
inactive forms are created to stop the cell from reacting to too much hormone and remain 
in the cytoplasm (Anyetei-Anum et al. 2018). 
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Thyroid hormones have widespread effects ranging from metabolism to 
reproduction.  The HPT axis is also very active during development.  In response to cold 
temperatures, thyroid hormone is upregulated due to its thermogenic effects.  Thyroid 
hormone increases metabolic rate, therefore increasing heat production.  Hypothyroidism 
also has been shown to slow sexual maturation and increase hair loss.  During 
development, sufficient levels of thyroid hormone are necessary for nervous system 
growth.  If levels are low during nervous system development, there can be serious 
deficits in function (Norris 2006).   
IV. Thyroid Hormone Receptors 
TRs are primarily nuclear proteins that bind to DNA, usually as a heterodimer 
with retinoid X receptor (RXR), to regulate gene expression, either through activation or 
repression.  TRs can bind to DNA independently, meaning the presence of T3 is not 
required for action.  When bound to T3, TRs bind to coactivators that aid in the activation 
of gene expression.  When T3 is not present, TRs interact with “positive” thyroid 
hormone response elements (TREs) that act in conjunction with corepressors to inhibit 
gene expression.  On the other hand, “negative” TREs have the opposite effect.  When T3 
is absent, TRs activate transcription (Zhang et al. 2018).  TRs have two classes (TRα and 
TRβ) and four major isoforms (TRα1, TRα2, TRβ1, and TRβ2) stemming from two 
genes, Thra and Thrb (Sidhaye & Wondisford 2012).  Thyroid hormones act on all 
tissues of the body, so their receptors must also be present in all tissues.  However, the 
distribution of TRs is not equal.  TRα1 is the most prevalent form in bone, the 
gastrointestinal tract, muscle and the central nervous system (Zhang et al. 2018).  
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Alternatively, TRβ1 is predominantly located in the liver, kidney, and ear (Anyetei-Anum 
et al. 2018). 
V. Thyroid Hormone Receptor Domains 
TRs have four domains, like all members of the nuclear receptor superfamily: the 
A/B domain (A/B) at the N-terminus that varies widely between family members, a 
DNA-binding domain (DBD), a ligand-binding domain (LBD) at the C-terminal end, and 
a hinge region that connects the DBD and LBD (Anyetei-Anum et al. 2018) (Fig. 3).  The 
A/B domain in both major isoforms (TRα1 and TRβ1) contains the activation function 1 
domain (AF-1), which is important for the regulation of transcription (Zhang et al. 2018).  
The hinge region, as well as linking the two biggest functional domains, has functions in 
DNA binding, ligand binding, and interactions with other transcription factors effecting 
repression and activation (Anyetei-Anum et al. 2018). 
The LBD is the largest single domain of the TRs.  It is made up of twelve α-
helices that create a hydrophobic binding site for T3.  When T3 is not bound, the twelfth 
helix is in an open position, which exposes the binding site and allows for easier binding 
of the hormone.  After T3 binds, the helix undergoes a conformational shift that closes off 
the pocket and allows for coactivators to bind.  Within helix-12 is a ligand-dependent 
activation domain (AF-2), that has little variation across the entire nuclear receptor 




Figure 3: Structure of the domains of TRα1 and TRβ1.  Numbers represent the amino 
acids that form borders between domains and sequences.  A/B- A/B domain; DBD- 
DNA-binding domain; LBD- Ligand-binding domain; NLS- nuclear localization signal; 
NES- nuclear export signal;  
H- helix; star- represents R384C/H- point of mutation, arginine to cysteine/ histidine.  
(Not to scale) 
 
VI. Nuclear Localization 
While TRs are mostly localized to the nucleus, they undergo constant shuttling 
between the cytoplasm and nucleus (Bunn et al., 2001).  This is mediated by multiple 
nuclear localization signals (NLSs) and nuclear export signals (NESs).  NLS-1 is found in 
both TRα1 and TRβ1 in the hinge domain (see Fig. 3).  It is a classic NLS and is enough 
to cause movement into the nucleus on its own.  Not present in TRβ1, a second NLS 
(NLS-2) was found in the A/B domain of TRα1 (Mavinakere et al. 2012).  NLS-2 is a 
shorter, nonclassical sequence and is necessary for the receptor to be transported into the 
nucleus in an efficient manner.  TRβ1 has been shown consistently to have a larger 
cytosolic population than TRα1, suggesting that the presence of the second NLS alters 
the balance between import and export signaling (Zhang et al. 2018). 
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The nucleus is surrounded by a double membrane called the nuclear envelope, 
which is easily crossed by small molecules.  Larger molecules, such as proteins larger 
than 50 kDa, must move through nuclear pore complexes (NPCs), large protein 
complexes that act as gatekeepers.  Movement through NPCs is usually aided by 
members of the karyopherin β-like family, importins and exportins (Kubitscheck & 
Siebrasse 2017) (Figure 4).  The presence of multiple NLSs in TRα1 suggests the 
possibility of multiple paths into the nucleus.  The NLS in the hinge domain interacts 
with a heterodimer of importin α1 and importin β1 in the classical import pathway.  NLS-
2 in TRα1 interacts with importin 7, a protein that is known to work with a large range of 
targets and interact with importin β1 (Roggero et al., 2016).   
Nuclear export of TRs seems to be mediated by three distinct NESs found in 
helices three, six, and twelve (NES-H3, NES-H6, and NES-H12), all found within the 
LBD (see Fig. 3) (Mavinakere et al., 2012).  Helix 12, as previously mentioned, plays an 
important role in ligand binding and contains AF-2.  The overlap between AF-2 and 
NES-H12 suggests that there may be competition that leads to the delicate balance 
between export and nuclear retention.  It is also known that NES-H12 plays a vital role in 
nuclear export.  NES-H3 and NES-H6 are both highly conserved between all TRs and 
overlap with regions of the LBD important for the recruitment of corepressors during 
gene suppression (Zhang et al. 2018). 
 The export of TRα1 seems to be dependent on two separate pathways, CRM1-
dependent and CRM1-independent.  The CRM1 (chromosome maintenance factor 1), or 
exportin 1, works in conjunction with calreticulin, a protein that binds to calcium, to 
move cargo out of the nucleus (Grespin et al., 2008).  The CRM1-independent pathway 
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relies on exportins 4, 5, and 7 (Subramanian et al., 2015) (Fig. 4).  This pathway was first 
discovered after cells were treated with leptomycin B, a known inhibitor of CRM1, and 
TRα1 was still exported from the nucleus (Bunn et al., 2001). 
 
Figure 4: Overview of Nuclear Trafficking of TRα1  
VII. Resistance to Thyroid Hormone Syndrome 
Resistance to thyroid hormone (RTH) syndrome arises from mutations in the 
genes coding for TR in the ligand binding domain, with the majority of the mutations 
occurring in the regions associated with NES-H12 and NES-H3/H6 (Anyetei-Anum et al. 
2018, Dumitrescu & Refetoff 2013).  These mutations lead to decreased ligand-binding 
and some have dominant negative activity.  Due to their location, it would appear that the 
mutations, in addition to interfering with binding T3, could affect localization of the 
Nucleus 
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receptors within the cells (Zhang et al. 2018).  RTH can be caused by mutations in both 
TRα1 and TRβ1, although it was thought for a long time that only mutations in the beta 
form would lead to RTH.  The first reported case of RTHα did not come until 2012.  This 
delay was due in part to RTHα patients having near normal thyroid function despite being 
in a state of hypothyroidism (Vlaeminck-Guillem et al. 2015).   
Many mutations have been shown to cause the RTH phenotype, single amino acid 
changes like the mutants studied in this thesis to frameshift mutations that cause 
truncations at the C-terminal end of the receptor (Vlaeminck-Guillem et al. 2015).  One 
such truncation in TRα1, A382PfsX7, causes the receptor to stop at amino acid 388, 
cutting off the last 22 amino acids.  This mutation does not cause a large shift in 
subcellular localization but does lead to a textbook RTHα phenotype (Passero 2018).  
Due to the extremely similar natures of TRα1 and TRβ1 and the similar locations of 
many of the mutations, it has been speculated that the incidence of RTHα is actually 
comparable to the incidence of RTHβ (1/40,000) (Demir et al. 2016).  Both syndromes 
are associated with mutations that result in dominant negative activity, meaning that the 
mutated proteins will interfere with the function of the wild-type receptors (Moran & 
Chatterjee 2015).  RTHα differs from RTHβ, however, in multiple ways, most notably 
RTHα patients have normal thyroid function tests and the absence of goiter as a 
symptom.  RTHα is characterized by some intellectual deficits, smaller stature, abnormal 
bone development, and constipation (Vlaeminck-Guillem et al. 2015).  Slightly elevated 
levels of TSH and a high T3/T4 ratio are also commonly found in patients with RTHα 
(Demir et al. 2016, van Mullem et al. 2013).  Patients with RTHα also tend to suffer from 
mild anemia due to slowed differentiation of red blood cells (van Gucht et al. 2017).  
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RTHα has been characterized as a dominantly-inherited or sporadic disorder because the 
syndrome is found to run in families and some of the associated mutations have been 
found de novo (Moran & Chatterjee 2015).  
VIII. Mutants R384C and R384H 
Both mutations studied in this thesis are found at arginine-384, a site in the LBD 
near NES-H12 (see Fig. 3), and both mutations have been found to have equivalent 
mutations at the corresponding site on TRβ1 in other individuals with RTH (Demir et al. 
2016).  The first mutation, hTRα1_R384C, involves a missense mutation in which the 
arginine at 384 is switched to a cysteine (Fig. 5).  R384C was identified in one girl but 
nothing has been reported about her presentation of the syndrome other than the fact that 
she was a carrier for a form of autism, which suggests a potential link between the two 
disorders (Vlaeminck-Guillem et al. 2015).  This mutation has been heavily studied in 
mouse models.  Mice with the R384C mutation showed serious growth and development 
delays after birth, but the issues resolved relatively quickly without treatment (Demir et 
al. 2016).  In addition, R384C was associated with a massive decrease in binding affinity 
for T3, although this could be treated through the administration of T3.  The mice also 
overcame the size deficits that accompanied this issue.  However, the mice showed 
relatively severe deficits in psychomotor abilities, especially grip strength, coordination, 
and an altered gait; and they also had much higher levels of anxiety and less cognitive 





Figure 5: Structures of three amino acids involved in TRα1 mutations. Yellow highlight 
represents side chain.  Arginine- basic (positive at physiological pH); Cysteine- polar 
(neutral at physiological pH); Histidine- basic (positive at physiological pH). 
 
The second mutation studied in this thesis research consists of a missense 
mutation in which the arginine at position 384 is switched to a histidine (Fig. 5).  R384H 
is better characterized in human subjects, found in multiple members of the same family, 
and is associated with minor cognitive deficits and major motor deficits during 
development (Demir et al 2016).  At 16 months, infants are expected to be forming 
syllables and standing and walking with assistance and soon be starting to say full words 
and walk and stand independently; however, the patient showed delays in these skills 
(Demir et al 2016, Hadders-Algra 2018).  Later in life, most of the symptoms had 
lessened or cleared up, suggesting that the mutation causes the most issues at an earlier 
stage of life.  Luciferase reporter assays and Western blots were used to show that the 
mutation has a relatively small effect on the function of the receptor in vitro. Lower 
transcriptional activity was observed for T3-responsive genes, but this could be treated 
with increased T3.  When concentrations of T3 were increased, the function of the 
receptor reached normal levels (Demir et al. 2016).  
IX. Specific Aims of Thesis  
This paper investigated two TR1 mutants, R384C and R384H, which have both 
been implicated in RTHα.  Their patterns of localization within the cell were compared to 
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that of the wild type receptor to understand whether loss of nuclear localization of the 
receptor could contribute to the symptoms of RTHα.  
Methods  
I. Fluorescent Fusion Proteins 
The coding regions of wild-type TRα1 and mutant forms hTRα1_R384C and 
hTRα1_R384H were created using GeneArt Gene Synthesis, and then cloned into GFP 
expression plasmids by Vincent Roggero.  
II. Plasmid Preparation  
The plasmids were transformed into host E. coli. One ng of plasmid DNA was 
added to competent C2987H E. coli cells (New England BioLabs) and then the mixture 
was inverted five times.  The mixture was placed in an ice-bath for ten minutes, then 
exposed to heat for 30 seconds in a 42º C water bath.  The mixture was then returned to 
the ice for a further three minutes.  200 µl of room temperature SOC medium was added 
to the mixture.  Then, 100 µl of the mixture was spread onto a kanamycin-agar plate.  
The agar plate was then incubated for 24 hours at 37º C. 
Starter cultures containing 3 mL of LB media and 30 µg/mL of kanamycin were 
inoculated with individual colonies from the plate.  The starter cultures were allowed to 
grow at 300 rpm, 37º C for eight hours.  1 mL of starter culture was used to inoculate a 
culture of 50 mL of LB media and 30 µg/mL of kanamycin which had grown to 
saturation at 300 rpm, 37º C for 24 hours.  Then the cultures were centrifuged at 6000x g 
for ten minutes at 4º C.  Plasmids were purified from the pellet using Zymo Research 
ZyppyTM Plasmid Midiprep Kit.  The concentration of the purified plasmids was 




III. Cell Culture 
HeLa (human) cells were grown in GibcoTM Minimum Essential Medium (MEM) 
with 10% fetal bovine serum (FBS) at 37º C, 5% CO2, and 98% humidity.  When cells 
were ~90% confluent in the bottom of the flask, they were washed with 1x D-PBS and 
detached with 0.25% trypsin solution before being added to a new flask or prepared for 
transfection. 
IV. Transfection 
HeLa cells were seeded at a density of 2.0x105 cells/well onto coverslips that 
were placed in a six-well plate and left overnight.  Two µg of plasmid DNA was diluted 
with 250 µl of Opti-MEM per well.  The solution was then left at room temperature for 
five minutes.  In a separate tube, 24 µL of Lipofectamine 2000 was diluted with 1500 µl 
of Opti-MEM solution and also left for five minutes.  The Lipofectamine-Opti-MEM 
solution was then mixed with the DNA-Opti-MEM solution and incubated at room 
temperature for twenty minutes.  500 µL of Lipofectamine-DNA-Opti-MEM was added 
to each well, so that each well contained 4 µl of Lipofectamine, 2 µg of DNA, and 500 µl 
of Opti-MEM. 
The cells were incubated at 37º C, 5% CO2, and 98% humidity for anywhere from 
five to eight hours.  Subsequently, the solution was aspirated off, and 2 mL of MEM with 
10% FBS was added to each well.  Cells were incubated in the same conditions for a 





V. Fixation and Staining 
The media was aspirated off the wells in the six-well plate, and cells were washed 
three times for fifteen seconds each, using 2 mL of 1x D-PBS.  Cells were then fixed for 
ten minutes in a previously prepared 3.7% formaldehyde solution in 1x D-PBS solution.  
The formaldehyde solution was removed, and the cells went through three washes of 2 
mL of 1x D-PBS for five minutes each.  The coverslips were then inverted and mounted 
on glass slides using Fluoro-Gel II with DAPI, a DNA-specific fluorescent dye. 
VI. Scoring and Analysis 
Prepared slides were scored on an inverted fluorescence microscope using 
Nikon® NIS-Elements microscope imaging software.  Fluorescence was measured in two 
regions of each cell: one in the nucleus and one in the cytoplasm.  This measurement was 
done using two identical regions of interest (ROIs).  For cells that contained aggregates, 
the ROIs were positioned to capture representative fluorescence levels of the whole cell.  
The GFP tag was used to visualize the localization of TR1, and DAPI was used to 
visualize the nucleus of the cell.  Ratios of nuclear to cytoplasmic fluorescence were 
determined through analysis with Microsoft Excel. 
Three biologically independent replicates of three slides were scored for each 
mutant and the wild-type with a total of 100 cells measured per slide.  A Student’s T-Test 
was completed to test for a significant difference between the means of the samples.  A p-
value of less than 0.05 was considered significant. 
VII. Structural Analysis In silico with I-TASSER Server 
Amino acid sequences of wild type receptor and mutants, R384C and R384H, 
were entered into the I-TASSER server.  This calculated the normalized B-factor 
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predictions, which predict the stability of each amino acid position.  The sequences were 
then grouped based on domain and an average normalized B-factor was calculated for 
each domain, which gave relative stability of the domain.  A paired student T-test was 
performed to compare each mutant domain to the wild type to determine whether stability 
was significantly affected.  The mutants and wild type receptors were visualized using 
Chimera to understand which amino acid interactions were causing the stability changes.  
This analysis was performed by Jerry O’Dwyer. 
Results 
I. hTRα1_R384C is significantly more cytoplasmic than wild type TRα1 
To investigate the effect on receptor subcellular localization of a missense 
mutation that causes an amino acid substitution in the LBD of TRα1 that is linked to 
RTHα, HeLa cells were transfected with expression plasmids for GFP-tagged wild type 
TRα1 and hTRα1_R384C.  The patterns of distribution were compared using 
fluorescence microscopy and the nucleus to cytoplasmic fluorescence ratio (N/C) was 
calculated.  As expected, wild type TRα1 showed a primarily nuclear localization with a 
smooth distribution, with an N/C ratio of 9.00 (Fig. 6). In striking contrast, the mutant 
hTRα1_R384C had a mean N/C ratio of 3.05, indicating a large cytoplasmic shift 
compared to the wild type (Figs. 6, 7).  The calculated p-value was much less than 








Figure 6: HeLa cells were transfected with GFP-wild type TRα1 and GFP-TRα1 
R384C mutant expression plasmids, fixed, and stained with DAPI, and analyzed by 
quantitative fluorescence microscopy.  In the images, green fluorescence represents GFP-
TRα1 and blue fluorescence represents the DAPI-stained nucleus. 
 
Figure 7: Bars of graph show the relative N/C ratio for wild type and mutant TRα1-





II. hTRα1_R384H is significantly more cytoplasmic than wild type TRα1 
To investigate the effect on receptor localization within the cell of another single 
amino acid substitution in the LBD of TRα1 that is connected to RTHα, HeLa cells were 
transfected with expression plasmids for GFP-tagged wild type TRα1 and 
hTRα1_R384H.  The patterns of distribution were compared using fluorescence 
microscopy and the nucleus to cytoplasmic fluorescence ratio (N/C) was calculated.  
Similar to the hTRα1_R384C mutant, the hTRα1_R384H mutant had a much larger 
cytoplasmic population than the wild type receptor, with an N/C of 3.03, compared with 
an N/C of 9.00 for wild type (Figs. 8 and 9).  The T-test gave a p-value of much less than 
0.0001, indicating that the data are significant.   
 
Figure 8: HeLa cells were transfected with GFP-wild type TRα1 and GFP-TRα1 
R384H mutant expression plasmids, fixed, and stained with DAPI, and analyzed by 
quantitative fluorescence microscopy.  In the images, green fluorescence represents GFP-







Figure 9: Bars of graph show the relative N/C ratio for wild type and mutant TRα1-




Two RTHα-associated mutations, R384C and R384H, in TRα1 were investigated 
to see if their intracellular localization was different than that of wild type TRα1.  Both 
mutants were found to have a large shift from the nucleus into the cytoplasm.  This 
means that mislocalization of the receptor could potentially contribute to what is causing 
RTHα in the patients with these mutations.  
TRs are members of a large superfamily of nuclear receptors that act as 
transcription factors to regulate gene expression (Zhang et al. 2018).  One other member 
of this family that is closely related to TR is the vitamin D receptor (VDR), which also 
has a highly conserved LBD made up of 12 α-helices (Molloy & Feldman 2011).  A 
single amino acid substitution, R391C, in the LBD of VDR leads to hereditary 
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hypocalcemic vitamin D-resistant rickets (HVDRR) in patients.  This mutation has 
decreased transcriptional activity and reduced heterodimerization of VDR with RXR.  
These effects were found to be treatable with the addition of excess amounts of Vitamin 
D analogs.  This substitution is found near the C-terminal end of VDR and only a few 
amino acids away from the AF-2 domain (Whitfield et al. 1996).  R391C is a very similar 
mutation to the ones studied in this paper.  Its location in VDR is equivalent to the 
location of R384C and R384H in TRα1, all three mutations reduce transactivation and 
can be treated by increasing the levels of the related ligand, and they lead to the 
resistance of the receptor to its ligand. 
I. Structural implications of the mutation in the ligand binding domain of 
hTRα1_R384C 
The switch from an arginine to a cysteine at position 384 in TR1 is a rather large 
shift in the properties of the amino acid functional groups.  Both amino acids are polar, 
but arginine carries a positive charge at physiological pH and cysteine is neutral.  This 
switch causes a relatively major change within the protein, but the change is not in the 
LBD, it’s in the hinge domain.  The hinge domain is the link between the DBD and LBD 
(see Fig. 3).  It has elements important for DNA and T3 binding and activation and 
repression, but the hinge domain is also flexible enough to allow the receptor to change 
its conformation to allow binding of TREs (Zhang et al. 2018).  This increase in stability 
can be seen in Figure 10.  Figure 10A shows the wild type receptor hinge domain and the 
eighteen interactions between side chains in the hinge domain and the amino acids in the 
DBD and LBD.  Figure 10B shows the same region of the mutant R384C and the twenty-
six connections between those same residues.  Of the eighteen contacts in the wild type, 
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four are between the hinge domain and residues in the NES-H3/H6.  In the mutant, that 
number decreases to three contacts, suggesting that the NES is more exposed and 
potentially better able to recruit exportins and move to the cytoplasm. 
The hinge domain also contains NLS-1, which is an important factor for moving 
TRα1 into the nucleus (Anyetei-Anum et al. 2018).  Within the wild type receptor, there 
is only one contact between the hinge domain and the NLS, while there are two in the 
mutant.  A more stable hinge domain with a more closed off NLS suggests a difficulty 
moving TRα1 into the nucleus, which matches what was found in the cells expressing 
hTRα1_R384C.  It is not known, however, whether this mutation completely inhibits 
access to NLS-1, as TRα1 has two NLS domains.  This mutation could completely block 








Figure 10: View of TRα1 with hinge domain in foreground. Yellow- mutated position; 
White- stabilizing contacts; Blue- NLS; Purple- NES A) Wild type TR. B) 
hTRα1_R384C mutant. 











II. Structural implications of the mutation in the ligand binding domain of 
hTRα1_R384H 
Arginine to histidine does not seem like that large of a shift, as both amino acids 
have basic R-groups and a positive charge at physiological pH.  The main difference 
stems from the aromatic ring in the histidine side chain.  In Figure 11, the region of the 
receptor where the mutation is located, and the difference in the structure can be seen.  
The histidine residue increases the stability of the LBD.  In Figure 11A which shows the 
wild type receptor, it can be seen that R384 interacts with aspartate-208 and that is the 
only interaction within a five Angstrom radius of the mutation.  In Figure 11B, R384H 
now interacts with leucine-292 and in that same region there are now five interactions.  A 
couple of those interactions come from two nearby phenylalanine residues whose rings 
are in a stacked position.  Phenylalanine residues have a strong propensity to interact and 
often stabilize α-helices.  The bond can store up to 3.3kJ/mol of energy, making them 
highly favorable and hard to break.  These interactions are achieved through pi-pi 
interactions between the rings.  Aromatic structures have free pi electrons that can move 
around the molecule, spreading out the negative charge and providing resonance 
structures.  When multiple aromatic structures interact with each other more resonance 
structures are created, increasing the stability (Arjana et al. 2012). 
The location of the R384H mutation falls with helix 12 (H12), a structure that is 
integral to ligand-binding.  For proper ligand-binding, H12 must be flexible and able to 
undergo a conformational shift.  By increasing the stability in this region, it would follow 
that ligand-binding would decrease.  As mentioned earlier, H12 contains both AF-2 and 
NES-H12, possibly leading to competitive binding between coactivators and exportins 
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(Zhang et al. 2018).  The R384H mutation potentially inhibits AF-2 from being able to 
function properly, meaning exportins have a better chance to bind and move the receptor 
out of the cell.  This model would make sense with the findings that the hTRα1_R384H 








Figure 11: View of TRα1 looking at H12. Red- mutated position; Green- residue 
interacting with mutated amino acid; Orange- amino acids within 5 Å radius that have 
interactions; A) Wild type receptor. B) hTRα_R384H mutant. C) Overlay of both 
receptors. (Structures modeled with I-TASSER and image created using Chimera). 
 
III. Conclusion/ Future Directions 
In conclusion, the symptoms of RTHα derived from mutations R384C and R384H 
could be caused in part by a change in localization of the mutant receptors within the cell, 
but data presented in this thesis are not sufficient to say that localization is definitely the 
cause.  Mutations in TRα1 leading to RTH are a relatively new area of study.  More 
research should be targeted to determine whether these mutations do affect binding of 
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